p21 anticorps

N° du produit ABIN105216

Détail du produit anti-p21 anticorps

Antigène: p21 (CDKN1A) (Cyclin-Dependent Kinase Inhibitor 1A (p21, Cip1) (CDKN1A))

Reactivité: Humain

Hôte: Souris

Clonalité: Monoclonal

Conjugué: Cet anticorp p21 est non-conjugé

Application: Western Blotting (WB), ELISA, Immunohistochemistry (IHC)

Attributs du produit: Concentration Definition: by UV absorbance at 280 nm

Immunogène: This protein A purified monoclonal antibody was produced by repeated immunizations with recombinant human p21 fusion protein.
Immunogentype:Recombinant

Clone: WA-1

Isotype: IgG

Information d'application

Indications d'application: This antibody is suitable for immunohistochemistry, ELISA and immunoblotting. The antibody detects a 21 kDa band corresponding to the p21 protein.  MCF7 cells or UV treated fibroblasts are suggested as a positive control for immunoblotting and immunohistochemistry.   Methanol/acetone fixed tissue is reactive for immunohistochemistry. The antibody also reacts with breast carcinoma on frozen sections (methanol/acetone fixation) and on paraffin sections (formalin fixation and microwave treatment prior to staining).  In ELISA this monoclonal antibody is useful either as a capture antibody (attached to the solid phase) or for detection of p21 protein.  This antibody immunoprecipitates monomeric p21WAF1 and not p21 complexes with other proteins. High level expression of p21WAF1 requires induction of wild-type p53 expression (e.g. via exposure to DNA damaging agents).

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: 1.0 mg/mL

Buffer: 0.02 M Potassium Phosphate, 0.5 M Sodium Chloride, pH 7.2

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: -20 °C

Références pour anticorps anti-p21 (ABIN105216)

Supiot, Hill, Bristow: "Nutlin-3 radiosensitizes hypoxic prostate cancer cells independent of p53." dans: Molecular cancer therapeutics, Vol. 7, Issue 4, pp. 993-9, (2008) (PubMed).

Joshi, Chen, Kalemkerian, Adil, Kraut, Sarkar: "Inhibition of tumor cell growth by p21WAF1 adenoviral gene transfer in lung cancer." dans: Cancer gene therapy, Vol. 5, Issue 3, pp. 183-91, (1998) (PubMed).

Kagawa, Fujiwara, Hizuta, Yasuda, Zhang, Roth, Tanaka: "p53 expression overcomes p21WAF1/CIP1-mediated G1 arrest and induces apoptosis in human cancer cells." dans: Oncogene, Vol. 15, Issue 16, pp. 1903-9, (1997) (PubMed).

Yang, Perkins, Ohno, Nabel, Nabel: "The p21 cyclin-dependent kinase inhibitor suppresses tumorigenicity in vivo." dans: Nature medicine, Vol. 1, Issue 10, pp. 1052-6, (1996) (PubMed).

Waldman, Kinzler, Vogelstein: "p21 is necessary for the p53-mediated G1 arrest in human cancer cells." dans: Cancer research, Vol. 55, Issue 22, pp. 5187-90, (1995) (PubMed).

Yeh, Shatkin: "A cis-acting element in Rous sarcoma virus long terminal repeat required for promoter repression by HeLa nuclear protein p21." dans: The Journal of biological chemistry, Vol. 270, Issue 26, pp. 15815-20, (1995) (PubMed).

Détails sur p21

Antigène: p21 (CDKN1A) (Cyclin-Dependent Kinase Inhibitor 1A (p21, Cip1) (CDKN1A))

Autre désignation: p21 WAF1 (CDKN1A Produits)

Synonymes: anticorps CCND1, anticorps CDKN1A, anticorps CAP20, anticorps CDKN1, anticorps CIP1, anticorps MDA-6, anticorps P21, anticorps SDI1, anticorps WAF1, anticorps p21CIP1, anticorps CDKI, anticorps Cdkn1, anticorps Waf1, anticorps mda6, anticorps p21Cip1, anticorps p21WAF, anticorps Cip1, anticorps UV96, anticorps p21, anticorps cip1, anticorps p16Xic2, anticorps sdi1, anticorps waf1, anticorps cap20, anticorps cdkn1, anticorps mda-6, anticorps p21cip1, anticorps si:ch1073-48m5.2, anticorps KRAS2, anticorps p21ras, anticorps cyclin D1, anticorps cyclin dependent kinase inhibitor 1A, anticorps cyclin-dependent kinase inhibitor 1A (P21), anticorps cyclin-dependent kinase inhibitor 1A, anticorps cyclin-dependent kinase inhibitor 1A L homeolog, anticorps cyclin-dependent kinase inhibitor 1, anticorps KRAS proto-oncogene, GTPase, anticorps CCND1, anticorps CDKN1A, anticorps Cdkn1a, anticorps cdkn1a.L, anticorps cki1, anticorps cdkn1a, anticorps KRAS

Sujet: P21WAF1 is a tumor suppressor gene product critical to maintain proper regulatory control of cell division.  p21WAF1 inhibits cyclin/cyclin-dependent kinase (cdk) complexes, causing cell cycle arrest by blocking cell division at the S phase. Various mutations of tumor suppressor genes have been associated with different types of cancers.  In these cases, somatic gene therapy with wild-type versions of tumor suppressor genes have been contemplated as anti-cancer therapeutic approaches.  p21WAF1 contains p53-binding sites in its promoter and expression of p21WAF1 is induced in WI38 fibroblasts with PMA. The induction of and
Synonyms: Cyclin-dependent kinase inhibitor 1A (p21, Cip1) antibody, DNA Synthesis Inhibitor antibody, MDA 6 antibody, MDA6 antibody, Melanoma Differentiation Associated Protein 6 antibody

ID gène: 1026

NCBI Accession: NP_510867

UniProt: P38936

Pathways: Signalisation p53, Signalisation PI3K-Akt, Cycle Cellulaire, AMPK Signaling, Fc-epsilon Receptor Signaling Pathway, EGFR Signaling Pathway, Neurotrophin Signaling Pathway, Mitotic G1-G1/S Phases, DNA Replication, Hepatitis C, Synthesis of DNA, Autophagy